Suraj Mudichintala

Suraj Mudichintala is a Senior Associate at Action Potential Venture Capital, the corporate venture arm of GSK focused on bioelectronic medicine. Since joining the firm in June 2022, he has evaluated startups at the intersection of engineering, biology, and computation, supporting a portfolio of ten companies with typical investments ranging from $5 million to $10 million. He currently serves as a board member for Axon Therapies, guiding strategic development in the emerging neuromodulation sector where he recently noted strong deal flow. Previously, Mudichintala worked as an Associate at Arboretum Ventures from December 2018 to June 2022, leading due diligence efforts for biomedical and medical technology investments. After earning his undergraduate degree in management, finance, and business analytics from Boston College in 2016, he began his career with advisory roles at LEK Consulting and EY.